NeurMedix, LLC, a San Diego based privately held clinical stage pharmaceutical company announced that it has received authorization from the U.S. Food and Drug Administration’s (FDA) Office of Neuroscience, Division of Neurology I, to initiate a pivotal phase 3 clinical trial in Alzheimer’s disease with its lead clinical drug candidate, NE3107, 17α-ethynyl-androst-5-ene-3,7,17-triol.
February 2, 2021
· 7 min read